ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Tumor necrosis factor (TNF)"

  • Abstract Number: 0507 • ACR Convergence 2020

    Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study

    Grace Wright1, Peter Nash2, Laura Coates3, Jordi Gratacós4, Frank Behrens5, Kevin Ding6, Weibin Bao7, Luminita Pricop6, Corine Gaillez8 and Iain McInnes9, 1Association of Women in Rheumatology, New York, NY, 2School of Medicine Griffith University, Brisbane, Queensland, Australia, 3University of Oxford, Oxford, United Kingdom, 4University Hospital Parc Tauli Sabadell, Barcelona, Spain, 5CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, 6Novartis Pharmaceuticals Corporation, East Hanover, 7Novartis Pharmaceuticals Corporation, East Hannover, 8Novartis Pharma AG, Basel, Switzerland, 9Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Lower efficacy to anti-tumor necrosis factor treatment has been reported in female patients with psoriatic arthritis (PsA) as compared to males in clinical registries.1…
  • Abstract Number: 0573 • ACR Convergence 2020

    Effects of Successive Switches of Two Different Biosimilars of Etanercept on Outcomes in Inflammatory Rheumatic Diseases in Daily Practice

    Uta Kiltz1, Styliani Tsiami2, Xenofon Baraliakos1 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: A single switch from an originator to a biosimilar product has been shown to be safe and effective in the treatment of rheumatic musculoskeletal…
  • Abstract Number: 0801 • ACR Convergence 2020

    The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study

    Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Xue Han2, Joe Zhuo2, Amy Schrader1, Nicole Middaugh1, Page Moore1 and Vadim Khaychuk2, 1Corrona, LLC, Waltham, MA, 2Bristol-Myers Squibb Company, Princeton, NJ

    Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
  • Abstract Number: 0873 • ACR Convergence 2020

    Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Charlie Lovan5 and Alexis Ogdie6, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc., North Chicago, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: When deciding to start patients with PsA on biologic therapy, rheumatologists may focus on skin involvement in addition to joint symptoms. The purpose of…
  • Abstract Number: 0884 • ACR Convergence 2020

    Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Patrick Zueger4 and Alexis Ogdie5, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: There is no single accepted measure of low/minimal disease activity (LDA/MDA) for patients with PsA; thus, describing the characteristics of real-world patients meeting different…
  • Abstract Number: 0967 • ACR Convergence 2020

    Absence of Thy1 Associated with Severe Bone Loss in the TNF-transgenic (TNF-Tg) Mice Arthritis Model

    Ananta Paine1, Maria de la Luz Garcia-Hernandez2, Marc Nuzzo3, Stacey Duemmel3, Benjamin Korman1 and Christopher Ritchlin1, 1Department of Medicine, University of Rochester Medical Center, Rochester, NY, 2Department of Medicine, University of Rochester Medical Center, West Henrietta, NY, 3Department of Medicine, University of Rochester Medical Center, Rochester

    Background/Purpose: Thy1 (CD90) is a glycosylated, glycophosphatidylinositol (GPI)-anchored membrane protein noted to be expressed on many cells including T lymphocytes, stem cells, osteoblasts and fibroblasts.…
  • Abstract Number: 0998 • ACR Convergence 2020

    Differential Roles of TNFRI and TNFRII in the Morphology of Secondary Lymphoid Organs

    Kim Jeucken1, Jan Piet van Hamburg1 and Sander Tas2, 1Amsterdam Rheumatology and Immunology Center (ARC), Department of Rheumatology and Clinical Immunology, Department of Experimental Immunology and Amsterdam Infection and Immunity Institute, Amsterdam UMC; location AMC, University of Amsterdam, Netherlands, Amsterdam, Netherlands, 2Amsterdam Rheumatology and Immunology Center (ARC), Department of Rheumatology and Clinical Immunology, Department of Experimental Immunology and Amsterdam Infection and Immunity Institute, Amsterdam UMC; location AMC, University of Amsterdam, Netherlands, Utrecht, Netherlands

    Background/Purpose: Tumour necrosis factor (TNF) induced signaling events are important in lymphoid organ development and function, both in health and in immune-mediated inflammatory diseases such…
  • Abstract Number: 1366 • ACR Convergence 2020

    Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation

    Juergen Braun1, Ricardo Blanco2, Helena Marzo-Ortega3, Lianne Gensler4, Filip Van den Bosch5, Hideto Kameda6, Denis Poddubnyy7, Marleen van de Sande8, Anna Wiksten9, Brian Porter10, Santiago Moreno9, Abhijit Shete9, Hanno Richards9, Sibylle Haemmerle9 and Atul Deodhar11, 1Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany, 2Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 3The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, 4University of California San Francisco, San Francisco, CA, 5Ghent University Hospital, Ghent, Belgium, 6Toho University, Tokyo, Japan, 7Charité – Universitätsmedizin Berlin, Berlin, Germany, 8Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, 9Novartis Pharma AG, Basel, Switzerland, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ, 11Oregon Health & Science University, Portland, OR

    Background/Purpose: Active non-radiographic axial spondyloarthritis (nr-axSpA) is often determined on the basis of objective signs of inflammation (elevated C-reactive protein [CRP] and/or evidence of sacroiliitis…
  • Abstract Number: 1497 • ACR Convergence 2020

    COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance

    Bonnie Bermas1, Megan Clowse2, Milena Gianfrancesco3, Jonathan Hausmann4, Pedro M Machado5, Emily Sirotich6, Helen Robinson7, Anja Strangfeld8, Jinoos Yazdany9 and Philip Robinson10, 1UTSouthwestern.edu, Dallas, TX, 2Duke University, Chapel Hill, NC, 3University of California, San Francisco, San Francisco, CA, 4Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 5University College London, London, United Kingdom, 6McMaster University, Hamilton, ON, Canada, 7University of Queensland School of Medicine, HERSTON, Queensland, Australia, 8German Rheumatism Research Center, Berlin, Germany, 9UCSF, San Francisco, CA, 10University of Queensland, Herston, Queensland, Australia

    Background/Purpose: The impact of COVID-19 on pregnancy in patients with rheumatic disease is unknown. We describe COVID-19 outcomes in pregnant rheumatic disease patients reported to…
  • Abstract Number: 1895 • ACR Convergence 2020

    Radiographic Progression in Patients with Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)

    Maria Llop1, Mireia Moreno2, Jordi Gratacós3, Victoria Navarro-Compán4, Eugenio De Miguel5, Pilar Font6, Teresa Clavaguera7, Luis Francisco Linares8, Beatriz Joven9 and Xavier Juanola10, 1Hospital Universitari Parc Taulí I3PT, Sabadell, Catalonia, Spain, 2Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, 3University Hospital Parc Tauli Sabadell, Barcelona, Spain, 4Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 5Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, 6Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, 7Hospital Universitari Trueta, Girona, Spain, 8Hospital de la Arrixaca, Murcia, 9Hospital Universitario 12 de Octubre, Madrid, Spain, 10Rheumatology Service, University Hospital Bellvitge, IDIBELL, Barcelona, Spain, Barcelona, Spain

    Background/Purpose: Clinical efficacy of TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA) has been widely probed in randomized control trials. In clinical practice, some studies suggested…
  • Abstract Number: 2022 • ACR Convergence 2020

    Effects of Anti-TNF-therapy on Osteoblastic Activity in Ankylosing Spondylitis – Results from a Prospective Study Using PET-MRI of SIJ and Spine

    Xenofon Baraliakos1, Styliani Tsiami2, Christoph Rischpler3, Nils-Martin Bruckmann4, Wolfgang Fendler3, Julian Kirchner5, Ken Herrmann3, Lino Morris Sawicki5 and Juergen Braun6, 1Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 3Department of Nuclear Medicine, University Essen-Duisburg, Essen, Germany, 4Department of Radiology, University Duesseldorf, Düsseldorf, Germany, 5Department of Radiology, University Duesseldorf, Duesseldorf, Germany, 6Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany

    Background/Purpose: The clinical efficacy of TNFi in patients with axSpA is well established but its effect on new bone formation is still unclear. Positron emission…
  • Abstract Number: 1446 • 2019 ACR/ARP Annual Meeting

    Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany

    Klaus Krüger 1, Gerd Burmester 2, Siegfried Wassenberg 3, Astrid Thiele 4 and Matthias Thomas5, 1Medical Centre of Rheumatology, Munich, Germany, 2Charité—University Medicine Berlin, Berlin, Germany, 3Centre of Rheumatology, Ratingen, Germany, 4Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, 5MSD Sharp & Dohme GmbH, Haar, Germany

    Background/Purpose: The aim of this post hoc analysis is to assess effectiveness of GLM used as first, second, or at least third biologic agent in…
  • Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting

    Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?

    Santiago Rodrigues-Manica1, Alexandre Sepriano 2, Fernando Pimentel-Santos 1, Nélia Gouveia 3, Anabela Barcelos 4, Jaime Branco 1, Miguel Bernardes 5, Raquel Miriam-Ferreira 5, Elsa Vieira-Sousa 6, Sofia Barreira 6, Filipe Vinagre 7, Raquel Roque 7, Helena Santos 8, Nathalie Madeira 8, João Rovisco 9, Alexandra Daniel 9 and Sofia Ramiro 10, 1CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, 2Leiden University Medical Center, Leiden, Netherlands, 3CEDOC, NOVA-Medical School, Lisbon, Portugal, Lisboa, Portugal, 4Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, 5Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, 6Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, 7Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, 8Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 9Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Coimbra, Portugal, 10Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands

    Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…
  • Abstract Number: 1776 • 2019 ACR/ARP Annual Meeting

    Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study

    Dongze WU1, Priscilla Wong 1, Steven H.M. Lam 1, Isaac T. Cheng 1, Edmund K. Li 1, Ling Qin 1 and Lai-Shan Tam 1, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: Biologic agents targeting cytokines including TNF-α, IL-12p70 and IL-17 have been proven to be very effective in treating psoriatic arthritis (PsA).  Nonetheless, whether these…
  • Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting

    Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA

    Alexis Ogdie1, Ervant Maksabedian 2, Bradley Stolshek 2, Yomei Shaw 3 and Kaleb Michaud 4, 1University of Pennsylvania, Philadelphia, PA, 2Amgen Inc., Thousand Oaks, CA, 3FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 4FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS

    Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA).  One…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.